Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder.
- Authors
- Weinstock, Lauren M; Gaudiano, Brandon A; Wenze, Susan J; Epstein-Lubow, Gary; Miller, Ivan W
- Year
- 2016
- Journal
- Comprehensive psychiatry
- PMID
- 26773991
- DOI
- 10.1016/j.comppsych.2015.10.003
- PMCID
- PMC4715863
BACKGROUND: Published data suggest that cannabis use is associated with several negative consequences for individuals with bipolar disorder (BD), including new manic episode onset, psychosis, and functional disability. Yet much less is known about cannabis use disorders (CUDs) in this population, especially in more acutely symptomatic groups. METHODS: To evaluate correlates of CUD comorbidity in BD, a retrospective chart review was conducted for 230 adult patients with bipolar I disorder (BDI) who were admitted to a university-affiliated private psychiatric hospital. Using a computer algorithm, a hospital administrator extracted relevant demographic and clinical data from the electronic medical record for analysis. RESULTS: Thirty-six (16%) had a comorbid CUD. CUD comorbidity was significantly associated with younger age, manic/mixed episode polarity, presence of psychotic features, and comorbid nicotine dependence, alcohol use disorder (AUD), and other substance use disorders, but was associated with decreased likelihood of anxiety disorder comorbidity. With the exception of manic/mixed polarity and AUD comorbidity, results from multivariate analyses controlling for the presence of other SUDs were consistent with univariate findings. CONCLUSION: Patients with BD and comorbid CUDs appear to be a complex population with need for enhanced clinical monitoring. Given increasing public acceptance of cannabis use, and the limited availability of evidenced-based interventions targeted toward CUDs in BD, psychoeducation and other treatment development efforts appear to be warranted.
No figures extracted from this document.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A Prospective Comparison of Bipolar I and II Subjects with and without Comorbid Cannabis Use Disorders from the COGA Dataset. | 2023 | 37626487 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling. | Stoeva-Grigorova S et al. | — | 2025 | → |
| Cannabis use and mood disorders: a systematic review. | Sorkhou M et al. | — | 2024 | → |
| Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada - A Qualitative Study. | Das A et al. | — | 2024 | → |
| A Prospective Comparison of Bipolar I and II Subjects with and without Comorbid Cannabis Use Disorders from the COGA Dataset. | Preuss UW et al. | — | 2023 | → |
| Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. | Tourjman SV et al. | — | 2023 | → |
| Cannabis use and its relationship with bipolar disorder: A systematic review and meta-analysis. | Maggu G et al. | — | 2023 | → |
| Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2-Metabolome, immunome, synaptome. | Reece AS et al. | — | 2023 | → |
| Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1-aging and epigenomics. | Reece AS et al. | — | 2023 | → |
| Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence. | Kuhns L et al. | — | 2022 | → |
| Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. | Prisciandaro JJ et al. | — | 2022 | → |
| Sociodemographic and clinical correlates of cannabis dependence among Israeli combat veterans. | Asper A et al. | — | 2022 | → |
| A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. | Kozak K et al. | — | 2021 | → |
| Effects of the synthetic cannabinoid XLR-11 on the viability and migration rates of human brain microvascular endothelial cells in a clinically-relevant model. | Al-Eitan L et al. | — | 2020 | → |
| Sex differences in bipolar disorder: Impact of lifetime cannabis use on clinical course, functioning, and quality of life in bipolar disorder. | de la Fuente-Tomás L et al. | — | 2020 | → |
| Cannabis use disorder and suicide attempts in bipolar disorder: A meta-analysis. | Bartoli F et al. | — | 2019 | → |
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. | Yatham LN et al. | — | 2018 | → |
| Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. | Cohen K et al. | — | 2018 | → |
| Alcohol use disorders are associated with increased affective lability in bipolar disorder. | Lagerberg TV et al. | — | 2017 | → |
| TLR4 gene polymorphism associated with lifetime cigarette smoking in bipolar disorder. | Zerdazi EH et al. | — | 2017 | → |